HRP20040067A2 - Pharmaceutical compositions of amlodipine and atorvastatin - Google Patents

Pharmaceutical compositions of amlodipine and atorvastatin

Info

Publication number
HRP20040067A2
HRP20040067A2 HR20040067A HRP20040067A HRP20040067A2 HR P20040067 A2 HRP20040067 A2 HR P20040067A2 HR 20040067 A HR20040067 A HR 20040067A HR P20040067 A HRP20040067 A HR P20040067A HR P20040067 A2 HRP20040067 A2 HR P20040067A2
Authority
HR
Croatia
Prior art keywords
amlodipine
atorvastatin
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
HR20040067A
Other languages
English (en)
Inventor
Alani Laman
Ulla Khan Sadath
Michael Macnell Thomas
Abdul-Hussain Muhammad Nouman
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of HRP20040067A2 publication Critical patent/HRP20040067A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
HR20040067A 2001-07-31 2002-07-29 Pharmaceutical compositions of amlodipine and atorvastatin HRP20040067A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30913301P 2001-07-31 2001-07-31
PCT/IB2002/002988 WO2003011283A1 (en) 2001-07-31 2002-07-29 Pharmaceutical compositions of amlodipine and atorvastatin

Publications (1)

Publication Number Publication Date
HRP20040067A2 true HRP20040067A2 (en) 2005-02-28

Family

ID=23196829

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040067A HRP20040067A2 (en) 2001-07-31 2002-07-29 Pharmaceutical compositions of amlodipine and atorvastatin

Country Status (47)

Country Link
US (2) US20030114497A1 (de)
EP (2) EP1852116A1 (de)
JP (3) JP4020863B2 (de)
KR (2) KR100674762B1 (de)
CN (2) CN1617717A (de)
AP (1) AP1745A (de)
AR (1) AR034925A1 (de)
AT (1) ATE385793T1 (de)
AU (1) AU2002355680B2 (de)
BR (1) BR0211548A (de)
CA (1) CA2444554C (de)
CO (1) CO5540287A2 (de)
CR (1) CR7219A (de)
CY (1) CY1107245T1 (de)
DE (1) DE60225014T2 (de)
DK (1) DK1411923T3 (de)
DO (1) DOP2002000445A (de)
EA (1) EA006998B1 (de)
EC (1) ECSP044965A (de)
ES (1) ES2298381T3 (de)
GE (1) GEP20063926B (de)
GT (1) GT200200158A (de)
HN (1) HN2002000198A (de)
HR (1) HRP20040067A2 (de)
HU (1) HUP0401569A2 (de)
IL (1) IL159440A0 (de)
IS (1) IS7089A (de)
MA (1) MA27052A1 (de)
MX (1) MXPA04000270A (de)
MY (1) MY137519A (de)
NI (1) NI200200095A (de)
NO (1) NO20040405L (de)
NZ (1) NZ530247A (de)
OA (1) OA13300A (de)
PA (1) PA8551701A1 (de)
PE (1) PE20030324A1 (de)
PL (1) PL368519A1 (de)
PT (1) PT1411923E (de)
PY (1) PY0218256A (de)
RS (1) RS5304A (de)
SG (1) SG143982A1 (de)
SV (1) SV2003001189A (de)
TN (1) TNSN04022A1 (de)
UA (1) UA79750C2 (de)
UY (1) UY27402A1 (de)
WO (1) WO2003011283A1 (de)
ZA (1) ZA200400659B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
AU2005263550C1 (en) * 2004-07-16 2013-01-17 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
US7674923B2 (en) * 2004-09-28 2010-03-09 Teva Pharmaceutical Industries Ltd Process for preparing forms of atorvastatin calcium substantially free of impurities
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
EP1833466A1 (de) * 2004-12-28 2007-09-19 Ranbaxy Laboratories Limited Verfahren zur herstelulng von stabilen pharmazeutischen soliden dosierformen von atorvastatin und amlodipin
EP1863457A2 (de) * 2005-03-15 2007-12-12 Lupin Ltd. Pharmazeutische zusammensetzungen von amlodipin und benazepril
JP5330825B2 (ja) * 2006-03-29 2013-10-30 興和株式会社 トリグリセリド低下剤及び高インスリン血症改善剤
DE102006033723A1 (de) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe
KR100793321B1 (ko) * 2006-11-29 2008-01-11 사회복지법인 삼성생명공익재단 후각장애 치료 및 예방용 조성물
CN101433539A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和他汀类药物的治疗组合物
EP2070520A1 (de) 2007-12-11 2009-06-17 LEK Pharmaceuticals D.D. Pharmazeutische Zusammensetzung mit mindestens einem Wirkstoff und einem in einem sauren Medium quellenden Bindemittel
WO2009116061A2 (en) * 2008-01-10 2009-09-24 Alkem Laboratories Ltd. Stable oral pharmaceutical composition comprising atorvastatin
EP2165702B1 (de) 2008-09-17 2011-11-16 Helm AG Durch Nassgranulation hergestellte stabile und fertig gelöste Zusammensetzungen aus Candesartan-Cilexetil
US20110165239A1 (en) * 2008-09-24 2011-07-07 Laman Alani Pharmaceutical compositions of atorvastatin
EP2575757A1 (de) * 2010-06-03 2013-04-10 Mahmut Bilgic Wasserlösliche formulierung mit einer kombination aus amlodipin und einem statin
CN107028926A (zh) 2011-08-26 2017-08-11 国立大学法人大阪大学 糖尿病性心血管并发症的预防/治疗剂
JP2013231011A (ja) * 2012-05-01 2013-11-14 Sawai Pharmaceutical Co Ltd アトルバスタチン含有医薬組成物およびそれを用いた口腔内崩壊錠
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR20140028971A (ko) 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
CN109180701A (zh) * 2018-09-07 2019-01-11 中国药科大学 一种化合物2016a0c1药物组合物的共无定形物
KR102042626B1 (ko) 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
JP7660352B2 (ja) * 2019-09-02 2025-04-11 日本ジェネリック株式会社 アトルバスタチンカルシウム水和物及びエゼチミブを含む錠剤
CN111689922B (zh) * 2020-07-17 2022-03-15 江西施美药业股份有限公司 一种苯磺酸左旋氨氯地平环合杂质的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
KR100431038B1 (ko) * 1995-07-17 2004-05-12 워너-램버트 캄파니 엘엘씨 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CN1217656C (zh) * 1995-11-02 2005-09-07 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物
TR200000562T2 (tr) * 1997-08-29 2000-08-21 Pfizer Products Inc. Amlodifin ve bir statin bileşiği içeren bileşim terapisi
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
NZ503598A (en) * 1997-11-25 2002-06-28 Warner Lambert Co Hydroxylated gemfibrozil, atorvastatin and fluvastatin with antioxidant activity for inhibition of lipoprotein oxidation
DK1173172T3 (da) * 1999-04-23 2006-05-15 R Preston Mason Synergistiske virkninger af amlodipin og den hydroxylerede metabolit af atorvastatin
HN2000000050A (es) * 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
WO2002011723A1 (en) * 2000-08-04 2002-02-14 Mason R Preston Synergistic effect of amlodipine and atorvastatin

Also Published As

Publication number Publication date
AR034925A1 (es) 2004-03-24
RS5304A (sr) 2006-10-27
DK1411923T3 (da) 2009-01-05
CN101185646A (zh) 2008-05-28
MA27052A1 (fr) 2004-12-20
PA8551701A1 (es) 2003-02-14
EA200400028A1 (ru) 2004-08-26
EA006998B1 (ru) 2006-06-30
JP2007153908A (ja) 2007-06-21
DE60225014D1 (de) 2008-03-27
JP4020863B2 (ja) 2007-12-12
MXPA04000270A (es) 2004-05-04
JP2005501051A (ja) 2005-01-13
PE20030324A1 (es) 2003-04-03
NZ530247A (en) 2006-06-30
OA13300A (en) 2007-04-13
SG143982A1 (en) 2008-07-29
HN2002000198A (es) 2005-10-20
ZA200400659B (en) 2005-04-28
PT1411923E (pt) 2008-04-02
JP2007314566A (ja) 2007-12-06
IL159440A0 (en) 2004-06-01
NI200200095A (es) 2004-06-07
CA2444554A1 (en) 2003-02-13
ECSP044965A (es) 2004-03-23
UY27402A1 (es) 2003-02-28
TNSN04022A1 (fr) 2006-06-01
SV2003001189A (es) 2003-03-18
KR20040032148A (ko) 2004-04-14
CA2444554C (en) 2007-09-04
GEP20063926B (en) 2006-09-25
KR20060054495A (ko) 2006-05-22
BR0211548A (pt) 2004-07-13
AP1745A (en) 2007-05-30
CN1617717A (zh) 2005-05-18
AU2002355680B2 (en) 2007-11-15
AP2004002963A0 (en) 2004-03-31
DE60225014T2 (de) 2008-06-12
UA79750C2 (en) 2007-07-25
EP1411923B1 (de) 2008-02-13
DOP2002000445A (es) 2003-01-31
US20050107446A1 (en) 2005-05-19
CR7219A (es) 2004-03-24
US20030114497A1 (en) 2003-06-19
CO5540287A2 (es) 2005-07-29
PL368519A1 (pl) 2005-04-04
GT200200158A (es) 2003-05-15
EP1411923A1 (de) 2004-04-28
EP1852116A1 (de) 2007-11-07
IS7089A (is) 2003-12-22
HUP0401569A2 (hu) 2004-12-28
KR100674762B1 (ko) 2007-01-25
MY137519A (en) 2009-02-27
PY0218256A (es) 2004-03-01
WO2003011283A1 (en) 2003-02-13
ATE385793T1 (de) 2008-03-15
ES2298381T3 (es) 2008-05-16
CY1107245T1 (el) 2012-11-21
NO20040405L (no) 2004-03-08

Similar Documents

Publication Publication Date Title
IL159440A0 (en) Pharmaceutical compositions of amlodipine and atorvastatin
HUP0400451A3 (en) Pyrrole derivatives and pharmaceutical compositions containing them
HUP0501089A2 (en) Therapeutic isoquinoline compounds and pharmaceutical compositions coutaining them
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
HUP0400974A3 (en) Peptide-based compounds and pharmaceutical compositions containing them
HUP0303193A3 (en) Phthalayinone-piperidino-derivatives as pde4 inhibitors and pharmaceutical compositions containing them
HUP0303325A3 (en) Pharmaceutical salts and pharmaceutical compositions containing them
GB0111597D0 (en) Pharmaceutical compositions
HUP0202070A3 (en) Mutual salt of amlodipine and atorvastatin and pharmaceutical composition containing it
HUP0302456A3 (en) Combination pharmaceutical compositions containing of amlodipine and benazepril and their use and preparation
HUP0303998A3 (en) Phthalazinones derivatives and pharmaceutical compositions containing them
IL158671A0 (en) Benzyloxy derivatives and pharmaceutical compositions containing the same
GB0108470D0 (en) Pharmaceutical compositions and their use
PL353483A1 (en) Mutual prodrugs of amlodipine and atorvastatin
AU2001283085A1 (en) Synergistic effect of amlodipine and atorvastatin
ZA200508204B (en) Pharmaceutical composition of atorvastatin
HUP0401733A3 (en) Cyclic amine-derivatives and pharmaceutical compositions containing them
HUP0401572A3 (en) Alpha-ketoglutarates of l-carnitine and compositions containing same
GB0104752D0 (en) Pharmaceutical compositions
PL369268A1 (en) A stable pharmaceutical composition of pravastatin
HUP0402600A3 (en) D-proline derivatives and pharmaceutical compositions containing them
AU2002303552A8 (en) Methods and compositions for prevention of angioproliferation
IL153176A (en) Phenylpiperazines and pharmaceutical compositions comprising them
AU2002246659A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU2002246658A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080707

Year of fee payment: 7

OBST Application withdrawn